Orally active iron chelators

Blood Reviews

Volumn 16, Issue 2, 2002, Pages 127-134

  Merson, L ^a   Olivier, N ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cardiac disease; Deferiprone; Deferoxamine; Hepatic iron; Iron overload; Orally active chelating agents

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON CHELATE; UNCLASSIFIED DRUG; [4 [3,5 BIS(HYDROXYPHENYL) 1,2,4] TRIAZOL 1 YL]BENZOIC ACID;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LIVER FIBROSIS; PRIORITY JOURNAL;

EID: 0036304647     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2002.0009     Document Type: Article

References (77)

1. Iron-chelating therapy and the treatment of thalassemia
2. Iron chelators for thalassaemia
3. Hereditary hemochromatosis. Phenotypic expression of the disease
4. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients
5. Long-term survival in patients with hereditary hemochromatosis
6. Antenatal testing for haemoglobinopathies
7. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
8. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease
9. Hepatic iron concentration and total body iron stores in thalassemia major
10. Variability in hepatic iron concentration measurement from needle-biopsy specimens
11. Iron overload and liver fibrosis
12. Magnetic-susceptibility measurement of human iron stores
13. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry
14. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases
15. Evaluation of new iron chelators for clinical use
16. Animal toxicology of iron chelator L1
17. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice
18. A risk-benefit assessment of iron-chelation therapy
19. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload with the hydroxypyridinine iron chelator CP94
20. Ability of Deferiprone to protect tissues from non-transferrin-bound iron (NTBI) toxicity
21. Liver iron depletion and toxcicity of the iron chelator deferiprone (L1, CP20) in the guinea pig
22. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients
23. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease
24. Optimizing chelation therapy: Combining deferiprone and desferroxamine
25. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). 1. Iron chelation and metabolic studies
26. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major
27. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
28. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial
29. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
30. Iron-chelation therapy with oral deferipronein patients with thalassemia major
31. Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalasemia major
32. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
33. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
34. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
35. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine
36. A trial of deferiprone in transfusion-dependent iron overloaded children
37. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting
38. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)
39. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
40. Drug antioxidant effects. A basis for drug selection?
41. Stabilization of the iron (III) chelates of 1,2-dimethyl-3-hydroxypyrid-4-ones and related ligands
42. An orally active iron chelator
43. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells
44. Deferiprone fails to mobilize iron and promotes iron cardiotoxicity at suboptimal L1/iron concentrations
45. Oral iron chelation
46. A multi-center safety trial of the oral iron chelator deferiprone
47. Safety profile of the oral iron chelator deferiprone: A multicentre study
48. Long-term safety of the oral iron chelator deferiprone
49. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia
50. Long-term chelation therapy in thalassaemia major: Effect on liver iron concentration, liver histology, and clinical progress
51. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine
52. Binding of serum ferritin to concanavalin A: Patients with homozygous beta thalassaemia and transfusional iron overload
53. Combined therapy with deferiprone and desferrioxamine
54. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major
55. Combined oral and parenteral iron chelation in beta thalassaemia major
56. Deferoxamine-induced growth retardation in patients with thalassemia major
57. The toxic effects of desferrioxamine
58. Rapid desensitisation for desferrioxamine anaphylactic reaction
59. Rapid desensitization for desferrioxamine anaphylactoid reactions
60. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration
61. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia
62. Evaluation of a new method of administration of the iron chelating agent deferoxamine
63. Oral iron chelation therapy for thalassaemia: An uncertain scene
64. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
65. Cardiac failure and myocardial fibrosis in a patient with thalassemia major (TM) treated with long-term deferiprone
66. ICL670A, a tridentate orally active iron chelator provides net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia
67. Survival in medically treated patients with homozygous beta-thalassemia
68. Results of long-term iron-chelating therapy
69. Survival and disease complications in thalassemia major
70. New trends in the treatment of beta-thalassemia
71. Epidemiological situation and treatment of patients with thalassemia major in Germany: Results of the German multicenter beta-thalassemia study
72. Morbidity and mortality of iron intoxication in adult patients with thalassemia major, and effectiveness of chelation
73. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register